Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components

[1]  Jai-Sing Yang,et al.  The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin‐mediated cell death of human prostate cancer PC‐3 cells , 2014, Environmental toxicology.

[2]  Yingzhuo Shen,et al.  Myricetin induces apoptosis in HepG2 cells through Akt/p70S6K/bad signaling and mitochondrial apoptotic pathway. , 2013, Anti-cancer agents in medicinal chemistry.

[3]  S. Jung,et al.  Raf and PI3K are the Molecular Targets for the Anti‐metastatic Effect of Luteolin , 2013, Phytotherapy research : PTR.

[4]  Tingjun Hou,et al.  Feasibility of Using Molecular Docking-Based Virtual Screening for Searching Dual Target Kinase Inhibitors , 2013, J. Chem. Inf. Model..

[5]  A. Bracher,et al.  Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin , 2013, Molecular and Cellular Biology.

[6]  F. Sarkar,et al.  Dietary Agents in Cancer Chemoprevention and Treatment , 2012, Journal of oncology.

[7]  P. Morales,et al.  Selective apoptotic effects of piceatannol and myricetin in human cancer cells , 2012, Journal of applied toxicology : JAT.

[8]  Xianglin Shi,et al.  Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways , 2012, PloS one.

[9]  S. Ganatra,et al.  Inhibition Studies of Naturally Occurring Terpene based Compounds with Cyclin-Dependent Kinase 2 Enzyme , 2012 .

[10]  Yuan Yang,et al.  Triptolide Inhibits the Proliferation of Prostate Cancer Cells and Down-Regulates SUMO-Specific Protease 1 Expression , 2012, PloS one.

[11]  D. Heber,et al.  Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells , 2012, Nutrition and cancer.

[12]  Fang Sun,et al.  Potential Anticancer Activity of Myricetin in Human T24 Bladder Cancer Cells Both In Vitro and In Vivo , 2012, Nutrition and cancer.

[13]  A. González-Angulo,et al.  Targeting the PI3K signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[14]  S. Kazmirski,et al.  Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1). , 2011, Journal of medicinal chemistry.

[15]  Qingyi Zhu,et al.  [Quercetin induces the apoptosis of human PC-3 cells]. , 2011, Zhonghua nan ke xue = National journal of andrology.

[16]  Daniel J. Freeman,et al.  Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. , 2011, Journal of medicinal chemistry.

[17]  Liu Wei,et al.  mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets , 2011, The Journal of Nuclear Medicine.

[18]  Y. Tzeng,et al.  Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. , 2011, Chemical research in toxicology.

[19]  A. Baniahmad,et al.  The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth , 2011, Molecular and Cellular Endocrinology.

[20]  Yan Luo,et al.  Updates of mTOR inhibitors. , 2010, Anti-cancer agents in medicinal chemistry.

[21]  Tracey Clark,et al.  Design of selective, ATP-competitive inhibitors of Akt. , 2010, Journal of medicinal chemistry.

[22]  E. Antonarakis,et al.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer. , 2010, Cancer letters.

[23]  W. Sherman,et al.  Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. , 2010, Journal of chemical theory and computation.

[24]  R. Morphy.  Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[25]  Kwok-Kin Wong,et al.  Targeting the PI3K signaling pathway in cancer. , 2010, Current opinion in genetics & development.

[26]  V. Sivaramakrishnan,et al.  Morin fosters apoptosis in experimental hepatocellular carcinogenesis model. , 2010, Chemico-biological interactions.

[27]  J. Ungwitayatorn,et al.  Molecular docking study on anticancer activity of plant-derived natural products , 2010, Medicinal Chemistry Research.

[28]  Ki Han Kwon,et al.  Pharmacokinetics and Pharmacodynamics of Broccoli Sprouts on the Suppression of Prostate Cancer in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mice: Implication of Induction of Nrf2, HO-1 and Apoptosis and the Suppression of Akt-dependent Kinase Pathway , 2009, Pharmaceutical Research.

[29]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[30]  S. Amin,et al.  Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. , 2009, Cancer research.

[31]  Todd M Morgan,et al.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. , 2009, Current cancer drug targets.

[32]  M. López-Lázaro.  Distribution and biological activities of the flavonoid luteolin. , 2009, Mini reviews in medicinal chemistry.

[33]  Han-Ming Shen,et al.  Luteolin , a flavonoid with potentials for cancer prevention and therapy , 2009 .

[34]  J. Downward.  Targeting RAS and PI3K in lung cancer , 2008, Nature Medicine.

[35]  S. Marastoni,et al.  mTOR pathway and mTOR inhibitors as agents for cancer therapy. , 2008, Current cancer drug targets.

[36]  Jongsun Park,et al.  Contribution of Natural Inhibitors to the Understanding of the PI3K/PDK1/PKB Pathway in the Insulin-mediated Intracellular Signaling Cascade , 2008, International journal of molecular sciences.

[37]  Yong Lin,et al.  Luteolin, a flavonoid with potential for cancer prevention and therapy. , 2008, Current cancer drug targets.

[38]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  Yanli Wang,et al.  PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .

[40]  Chuanshu Huang,et al.  The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. , 2007, Current cancer drug targets.

[41]  Jai-Sing Yang,et al.  Morin inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway. , 2007, Anticancer research.

[42]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[43]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[44]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[45]  Yiwei Li,et al.  Using chemopreventive agents to enhance the efficacy of cancer therapy. , 2006, Cancer research.

[46]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[47]  H. Loh,et al.  Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[48]  Howard L McLeod,et al.  PI3K/Akt/mTOR pathway as a target for cancer therapy , 2005, Anti-cancer drugs.

[49]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[50]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[51]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[52]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[53]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[54]  G. Schwartsmann,et al.  Natural products in anticancer therapy. , 2001, Current opinion in pharmacology.

[55]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[56]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[57]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.